A Bispecific Immunotherapy for the Treatment of Melanoma

April 24, 2015

Mark R. Middleton, MD, PhD, discusses the results of a phase I/IIa trial of IMCgp100, a bispecific immunotherapy, for the treatment of patients with melanoma.

Mark R. Middleton, MD, PhD, a professor of experimental cancer medicine at the University of Oxford, discusses the results of a phase I/IIa trial of IMCgp100, a bispecific immunotherapy, for the treatment of patients with melanoma.

<<<